Brokerages Set COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Target Price at $15.88

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) has earned an average recommendation of “Moderate Buy” from the nine analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $15.8750.

A number of equities research analysts recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of COMPASS Pathways in a research report on Wednesday, October 8th. Morgan Stanley increased their target price on COMPASS Pathways from $10.00 to $11.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Finally, BTIG Research raised their price target on COMPASS Pathways from $7.00 to $14.00 and gave the company a “buy” rating in a report on Monday, October 13th.

Institutional Investors Weigh In On COMPASS Pathways

Several institutional investors have recently made changes to their positions in the stock. CWM LLC lifted its stake in shares of COMPASS Pathways by 19.2% in the third quarter. CWM LLC now owns 15,650 shares of the company’s stock valued at $90,000 after purchasing an additional 2,525 shares during the period. Conservest Capital Advisors Inc. increased its holdings in COMPASS Pathways by 32.5% in the second quarter. Conservest Capital Advisors Inc. now owns 20,363 shares of the company’s stock valued at $57,000 after buying an additional 5,000 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of COMPASS Pathways by 46.7% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company’s stock valued at $51,000 after acquiring an additional 5,817 shares during the period. Raymond James Financial Inc. boosted its stake in shares of COMPASS Pathways by 82.7% during the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock worth $79,000 after acquiring an additional 6,228 shares in the last quarter. Finally, Advisory Services Network LLC purchased a new stake in shares of COMPASS Pathways during the 3rd quarter worth approximately $41,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

COMPASS Pathways Stock Performance

Shares of CMPS opened at $6.90 on Tuesday. The stock has a market capitalization of $662.54 million, a P/E ratio of -2.54 and a beta of 1.92. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 1.23. COMPASS Pathways has a 1 year low of $2.25 and a 1 year high of $7.15. The company’s fifty day moving average is $6.01 and its two-hundred day moving average is $5.16.

COMPASS Pathways (NASDAQ:CMPS) last released its earnings results on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.02. On average, sell-side analysts predict that COMPASS Pathways will post -2.33 earnings per share for the current year.

About COMPASS Pathways

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.